@haleighweaver5's compounded GLP-1 claims, fact-checked

What did @haleighweaver5 actually say?

She kept it simple: before-and-after photos, a feeling of physical and mental improvement, and genuine enthusiasm. Her words were "I just feel so good physically and mentally" and she said she couldn't recommend it more. There were no specific dosing claims, no disease cure promises, just a personal testimonial about subjective wellbeing.

That restraint matters. A lot of GLP-1 content on TikTok makes specific clinical claims that go well beyond what the evidence supports. This video did not do that. What she described, feeling better physically and mentally while losing weight, is consistent with what researchers have actually measured in GLP-1 trials. The emotional tone is enthusiastic, but the factual footprint is small, which limits how much there is to actually fact-check here.

Does the science back this up?

Broadly, yes. The evidence that GLP-1 receptor agonists improve both physical and psychological outcomes is real and growing. The phrase "so much happier" is vague, but the sentiment maps onto documented findings.

The STEP 1 trial (Wilding et al., 2021, NEJM) showed that semaglutide 2.4mg weekly produced an average 14.9% body weight reduction in adults with obesity. But weight loss was not the only outcome. Participants reported meaningful improvements in physical functioning scores and quality-of-life measures. Separately, a 2023 analysis published in Nature Medicine (Blumenthal et al.) found that semaglutide users reported lower rates of depressive symptoms compared to baseline, though researchers are still untangling how much of that is driven by weight loss itself versus a direct neurochemical effect. Tirzepatide, which the caption also mentions, showed similar or greater weight loss in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), with participants also reporting improved wellbeing scores. So her subjective experience has a credible evidence base behind it.

What did they get wrong (or right)?

She got the personal experience part right, and credit where it is due, she did not overclaim. What is missing is honesty about the fuller picture, which is a different kind of problem than stating something false.

Her caption mentions "affordable compounded Semaglutide/Trizepatide" without any acknowledgment that compounded versions are not FDA-approved and are not equivalent to brand-name Wegovy or Zepbound. The FDA has specifically warned consumers about variability in compounded GLP-1 products, including inconsistent dosing and contamination risks. Compounded semaglutide is not the same product as Wegovy. That is not a technicality, it is a regulatory and clinical fact. The video also does not mention side effects. The STEP trials documented that over 70% of semaglutide users experience gastrointestinal side effects, most commonly nausea and vomiting. Presenting a transformation without that context is incomplete even if every individual claim she made was accurate.

What should you actually know?

The clinical evidence for GLP-1 agonists in weight management is genuinely strong. That part is not hype. But the compounded version framing in the caption deserves scrutiny from anyone watching.

Here is what the data actually says and what this video left out:

• Semaglutide and tirzepatide are among the most effective pharmaceutical tools for weight loss ever studied, but they work best alongside dietary and behavioral changes, not as standalone solutions.
• Compounded GLP-1 products exist in a regulatory gray zone. The FDA removed semaglutide from its drug shortage list in 2024, meaning most compounding pharmacies are no longer legally permitted to produce copies of it. Tirzepatide shortage status has been contested and varies by dose strength.
• The mental health improvements some users report are real but not universal. A 2024 review in Obesity Reviews noted that psychological outcomes vary significantly based on baseline mental health status, social support, and whether patients receive behavioral counseling alongside medication.
• Side effect rates are not trivial. Gastrointestinal symptoms affect the majority of users, and rare but serious risks including pancreatitis and thyroid C-cell tumors carry black box warnings on brand-name labeling.

Feeling good on a medication is a valid data point. It is just not the whole picture, and the caption's framing around affordability and compounding is where this video asks you to accept something the evidence does not fully support.